|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Other income | |||||
| Total revenues and other income | |||||
| Operating expenses | |||||
| Cost of revenue | |||||
| Research and development expenses | |||||
| Selling, general and administrative expenses | |||||
| Other operating income (expenses) | |||||
| Total operating expenses and other operating income | |||||
| Operating income (loss) | |||||
| Financial income | |||||
| Financial expenses | |||||
| Net Financial gain (loss) | |||||
| Tax income (expense) | |||||
| Income (loss) from continuing operations | |||||
| Income (loss) from discontinued operations | |||||
| Net income (loss) | |||||
| Attributable to shareholders of Cellectis | |||||
| Attributable to non-controlling interests | |||||
| Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis | |||||
| Basic net income (loss) attributable to shareholders of Cellectis, per share ($ /share) | |||||
| Diluted net income (loss) attributable to shareholders of Cellectis, per share ($ /share) | |||||
| Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) | |||||
| Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) | |||||
| Number of shares used for computing | |||||
| Basic | |||||
| Diluted |
Loading...
